Royalty Pharma plc Class A Ordinary Shares

RPRXNASDAQ • USD
ThemeAsset Mgmt & Capital Mkts›Private Equity & Alternative Investments
69.31 USD
↗ 0.34 (0.49%)AT CLOSE (03:59 PM EST)
68.64
↘ 0.67 (0.97%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
68.64
↘ 0.67 (0.97%)
🔴Market: CLOSED

Royalty Pharma plc Class A Ordinary Shares (RPRX) is currently trading at $69.31. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Nov 13, 2026.

Open?$68.77
High?$69.43
Low?$68.14
Prev. Close?$68.97
Volume?3.0M
Avg. Volume?3.4M
VWAP?$68.95
Rel. Volume?0.87x
Bid / Ask
Bid?$67.50 × 100
Ask?$70.00 × 200
Spread?$2.50
Midpoint?$68.75
Valuation & Ratios
Market Cap?30.9B
Shares Out?445.3M
Float?437.7M
Float %?98.3%
P/E Ratio?45.96
P/B Ratio?4.51
EPS?$1.51
Dividend?1.32%
Ex-Dividend?N/A
News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Themes
Asset Management & Capital Markets›Private Equity & Alternative InvestmentsBiotech - Drug Development›Clinical-Stage PlatformsHealthcare - Oncology›Immunotherapy & Immuno-Oncology
Employees
100
Market Cap
30.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.royaltypharma.com
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
54
Momentum?
73
Short Sent.?
57
Piotroski F-Score?4/9Mixed
Altman Z-Score?2.50Grey
Confidence?76%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?2.99%Low
Short Interest?13.1M
Days to Cover?4.0
Free Float437.7M
Avg Daily Volume3.3M
Settlement Date2026-10-30
Financial Health
Current Ratio?1.29Adequate
Quick Ratio?1.29Adequate
Cash Ratio?0.44Low
Debt/Equity?1.26Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
Peers
100
S&P
15
46.0PRICEY▾
P/B?
Peers
100
S&P
40
4.51FAIR▾
P/S?
Peers
100
S&P
6
11.79HIGH▾
P/FCF?
Peers
100
S&P
87
10.4CHEAP▾
EV/EBITDA?
Peers
100
S&P
19
22.3HIGH▾
EV/Sales?
Peers
100
S&P
3
14.89HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
34
9.8%FAIR▾
ROA?
Peers
50
S&P
31
3.5%FAIR▾
Cash Flow & Enterprise
FCF?$3.0B
Enterprise Value?$39.0B
Fundamentals ratios updated end of day
MarketsMoversWatchlist